Verification of Predictive Biomarkers for Pancreatic Cancer Treatment Using Multicenter Liquid Biopsy

This study is for verification of predictive biomarkers for pancreatic cancer treatment using multi-center liquid biopsy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pancreas Adenocarcinoma

Sex eligibility

All sexes

Study type

Observational

Primary location

NATIONAL CANCER CENTER 323, Ilsan-ro, Ilsandong-gu,

Goyang-si, Gyeonggi-do, 410-769, South Korea

About this study

Clinical applicability of KRAS mutations using circulating-tumor DNA in pancreatic cancer patients.

Quantification and monitoring of KRAS mutations Using droplet digital PCR in ctDNA extracted from collected patient samples.
Correlation analysis of KRAS mutation results with clinical data.

Discovery of biomarkers for predicting pancreatic cancer prognosis through ctDNA panel.

Gene panel composition for pancreatic cancer therapeutic target determination and monitoring.
A panel was performed using gDNA and ctDNA of tumor tissue collected from pancreatic cancer patients.
Comparative analysis of panel results and quantitative KRAS mutations and evaluation of clinical applicability.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with pathologically confirmed pancreatic adenocarcinoma.

Exclusion criteria

Patients disagree with the study.

Treatment and study plan

Primary outcomes

Clinical applicability of KRAS mutations

Time frame: Locally advanced and Resectable patients: Pre Treatment, 1,2,3,6,9,12,15,18,21,24months/ Metastatic patients: Pre Treatment, 1,2,4,6,8,10,12,14,16,18,20,22,24 months

Clinical applicability of KRAS mutations using circulating-tumor DNA in pancreatic cancer patients.
Discovery of biomarkers through ctDNA panel

Time frame: Locally advanced and Resectable patients: Pre Treatment, 1,2,3,6,9,12,15,18,21,24months/ Metastatic patients: Pre Treatment, 1,2,4,6,8,10,12,14,16,18,20,22,24 months

Discovery of biomarkers for predicting pancreatic cancer prognosis through ctDNA panel.

Sponsors and collaborators

Lead sponsor

National Cancer Center, Korea

Other Gov

Registry information

Important dates

Study start: 2019
Primary completion: 2021
Study completion: 2025
First posted: Jan 27, 2020
Registry last updated: Apr 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed